
• Reported GAAP EPS of -$0.21 up 41.67% YoY • Reported revenue of $20.85M down -9.47% YoY • ADC Therapeutics expects LOTIS-5 Phase 3 topline data in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end, and maintains an expected cash runway at least into 2028.
Bullish
ADC Therapeutics achieved increased net product revenues and reduced R&D expense, alongside anticipated Q2 2026 topline data for the pivotal ZYNLONTA LOTIS-5 Phase 3 trial.
Bearish
ADC Therapeutics experienced a decline in total net revenue to $20.85M, faced increased cost of product sales, and saw cash and cash equivalents decrease to $231M due to operations.